What did @juliesoria.fnp actually say?
Julie Soria, a family nurse practitioner, told her 207K viewers that starting GHK-Cu, the copper peptide, comes with a predictable list of benefits: "firmer skin, better elasticity, and collagen production, hair growth, better pigmentation" and, in her own experience, "crazy long eyelash growth." That is the full claim. No dosing, no mechanism, just a benefits list delivered with clinical confidence. Short video, big promises.
To her credit, she kept it relatively contained. She did not claim GHK-Cu treats any disease, and she did not stack it with anything dangerous on camera. But a list of expected outcomes said with authority to 200K people still carries weight, and some of those claims are better supported than others.
Does the science back this up?
Partially, yes. GHK-Cu has a legitimate and reasonably well-studied research profile, at least in the lab. The skin claims are the strongest. The eyelash claim is where the evidence gets thin fast.
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) has been studied since the 1970s. Pickart and Margolina (2018, Symmetry) published a detailed review showing GHK-Cu stimulates collagen synthesis, activates wound-healing genes, and upregulates antioxidant pathways in tissue. Multiple in vitro and some small clinical studies support its role in skin remodeling. A 2009 study by Leyden et al. (Journal of Cosmetic Dermatology) found topical GHK-Cu improved skin laxity and fine lines in a randomized trial, though the sample sizes were modest.
Hair growth has some support too. A 2007 study by Pickart found GHK-Cu enlarged hair follicle size in rodent models. Human data is limited but exists in small trials using topical formulations. The pigmentation claim, specifically less pigmentation, has some basis in GHK-Cu's known inhibition of melanin synthesis pathways, though this is largely in vitro data.
Eyelash growth? No published clinical evidence specifically for GHK-Cu. That claim appears to be personal anecdote, which is not science.
What did they get wrong (or right)?
The skin and collagen claims? Mostly right. The evidence base for GHK-Cu in collagen stimulation and skin elasticity is one of the more solid foundations in the peptide space. Soria is not making things up here, she is reflecting a real body of literature, even if she presents it as a certainty rather than a probability supported by mostly small trials.
The hair growth claim sits in the middle. Plausible, with some animal and limited human data, but far from established.
"Less pigmentation" is defensible in theory but should come with a caveat. GHK-Cu's effect on pigmentation is bidirectional in some research contexts, meaning it does not always behave the same way across skin types or formulations. Presenting it flatly as "less pigmentation" without nuance is an oversimplification.
"Crazy long eyelash growth" is a personal testimony, not a transferable clinical expectation. Presenting it as something viewers can "expect" after starting GHK-Cu is misleading, even if unintentionally so. Individual results driven by unknown variables should not be framed as predictable outcomes.
What should you actually know?
GHK-Cu is one of the more research-backed peptides in aesthetics, but that bar is still relatively low. Most studies are small, short, and industry-adjacent. The mechanisms are biologically plausible and the topical safety profile looks reasonable in the published data, but this is not FDA-approved for any of these uses in its peptide therapy form.
If you are considering GHK-Cu through a regulated telehealth platform, the conversation should include your skin goals, any underlying conditions that affect collagen metabolism, and realistic timelines. Results in clinical literature typically emerged over 8 to 12 weeks of consistent use in topical studies. Injectable formulations have far less published human data than topical.
The eyelash thing is not a reason to start a peptide protocol. Anecdote from a single provider, however credentialed, does not become population-level expectation just because it has 207K views. That is how misinformation spreads even through well-meaning clinicians.